Bicycle Therapeutics PLC SEC filings BCYC

Bicycle Therapeutics PLC has 660 filings in SEC EDGAR's recent list, going back to Dec 21, 2018. Its latest annual report, Form ARS, was filed on Apr 22, 2026 for the period ended Dec 31, 2025. The latest quarterly report (Form 10-Q) was filed on Oct 29, 2026, covering the quarter ended Sep 30, 2026. The most recent current report (Form 8-K) was filed on Oct 29, 2026 (results of operations). The company's fiscal year ends on December 31.

Bicycle Therapeutics PLC SEC filings
Form Description Filed Period
EFFECT Filing Aug 14, 2025 —
CORRESP Letter to the SEC Aug 12, 2025 —
UPLOAD Letter from the SEC Aug 12, 2025 —
D Filing Jun 12, 2024 —
EFFECT Filing Jun 15, 2020 —
CORRESP Letter to the SEC Jun 11, 2020 —
UPLOAD Letter from the SEC Jun 10, 2020 —
CT ORDER Filing May 24, 2019 —
EFFECT Filing May 23, 2019 —
EFFECT Filing May 22, 2019 —
CERT Filing May 22, 2019 —
CORRESP Letter to the SEC May 20, 2019 —
CORRESP Letter to the SEC May 20, 2019 —
8-A12B Filing May 20, 2019 —
CORRESP Letter to the SEC May 20, 2019 —
UPLOAD Letter from the SEC May 16, 2019 —
CORRESP Letter to the SEC May 13, 2019 —
UPLOAD Letter from the SEC May 7, 2019 —
CORRESP Letter to the SEC May 1, 2019 —
CORRESP Letter to the SEC Apr 26, 2019 —
UPLOAD Letter from the SEC Apr 4, 2019 —
DRSLTR Filing Mar 22, 2019 —
DRS/A Filing Mar 22, 2019 —
UPLOAD Letter from the SEC Feb 12, 2019 —
DRS Filing Dec 21, 2018 —

Showing 25 filings. Main filings leave out insider and ownership forms such as Form 4; choose a type above to see them. Each form opens on SEC.gov. Older filings are on SEC EDGAR.

Company profile

Industry
Pharmaceutical Preparations (SIC 2834)
Listed as
BCYC (Nasdaq)
Fiscal year ends
December 31
Incorporated in
United Kingdom
Headquarters
Cambridge, United Kingdom
SEC filer status
Non-accelerated filer, Smaller reporting company
SEC CIK
1761612
Former names
BICYCLE THERAPEUTICS Ltd (until May 24, 2019)

Other Pharmaceutical Preparations companies

Source: SEC EDGAR filings. This is company-reported data, not investment advice.